sigmaplot v.14 Search Results


sigmaplot/sigmastat v.13 package  (SPSS Inc)
90
SPSS Inc sigmaplot/sigmastat v.13 package
Sigmaplot/Sigmastat V.13 Package, supplied by SPSS Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/sigmaplot/sigmastat v.13 package/product/SPSS Inc
Average 90 stars, based on 1 article reviews
sigmaplot/sigmastat v.13 package - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
sigmaplot software v14.5 windows  (SPSS Inc)
90
SPSS Inc sigmaplot software v14.5 windows
Sigmaplot Software V14.5 Windows, supplied by SPSS Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/sigmaplot software v14.5 windows/product/SPSS Inc
Average 90 stars, based on 1 article reviews
sigmaplot software v14.5 windows - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
graphics software sigmaplot v14  (Jandel Engineering)
90
Jandel Engineering graphics software sigmaplot v14
Graphics Software Sigmaplot V14, supplied by Jandel Engineering, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/graphics software sigmaplot v14/product/Jandel Engineering
Average 90 stars, based on 1 article reviews
graphics software sigmaplot v14 - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
tukey post hoc test sigmaplot v. 14.0  (SYSTAT)
90
SYSTAT tukey post hoc test sigmaplot v. 14.0
pLTF is abolished following ESI-05 and PI828 treatment. A–D: representative traces of compressed, integrated phrenic nerve activity before and after sAIH following pretreatment with vehicle (A), ESI-05 (EPAC inhibitor, B), PI828 (PI3K/Akt inhibitor, C), and KT-5720 (PKA inhibitor, D). The dashed line in each trace represents baseline. E: phrenic burst amplitude (percent change from baseline) in vehicle (open diamonds)-, PKA inhibitor (filled squares)-, EPAC inhibitor (filled triangles)-, and PI3K/Akt inhibitor (filled circles)-treated rats after AIH, and time control (without AIH, gray diamonds)-treated rats. pLTF is significant in vehicle-treated rats versus EPACi-treated rats at 30-, 60-, and 90-min posthypoxia ($), and at all time-points post-AIH versus time control-treated rats (*), baseline (+), PKAi (#), and PI3K/Akti (&) (all P < 0.05). PKAi-treated rats showed significant pLTF versus baseline at 30-, 60-, and 90-min posthypoxia, and time control-treated rats at 90-min posthypoxia (all P < 0.05). F: frequency (change from baseline; bursts/min) in vehicle-, PKA inhibitor-, EPAC inhibitor-, and PI3K/Akt inhibitor-treated rats after AIH, and time control-treated rats. Small frequency LTF in vehicle-treated rats is observed at 30- and 60-min post-AIH versus baseline (+) (P < 0.05). PI3K/Akti-treated rats had decreased frequency LTF compared with baseline (+) at 15-min post-AIH (P < 0.05). A two-way ANOVA with repeated measures design was utilized, followed by a <t>Tukey</t> <t>post</t> hoc test. Values are means ± SE. AIH, acute intermittent hypoxia; EPAC, exchange protein activated by cyclic AMP; LTF, long-term facilitation; PI3K/Akt, phosphatidylinositol 3-kinase/Akt; pLTF, phrenic long-term facilitation; sAIH, severe AIH. The n for each group is as follows: vehicle 1, n = 10; ESI-05, n = 5; PI828, n = 5; KT-5720, n = 8; time control, n = 10.
Tukey Post Hoc Test Sigmaplot V. 14.0, supplied by SYSTAT, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/tukey post hoc test sigmaplot v. 14.0/product/SYSTAT
Average 90 stars, based on 1 article reviews
tukey post hoc test sigmaplot v. 14.0 - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
z-test sigmaplot v14  (SYSTAT)
90
SYSTAT z-test sigmaplot v14
pLTF is abolished following ESI-05 and PI828 treatment. A–D: representative traces of compressed, integrated phrenic nerve activity before and after sAIH following pretreatment with vehicle (A), ESI-05 (EPAC inhibitor, B), PI828 (PI3K/Akt inhibitor, C), and KT-5720 (PKA inhibitor, D). The dashed line in each trace represents baseline. E: phrenic burst amplitude (percent change from baseline) in vehicle (open diamonds)-, PKA inhibitor (filled squares)-, EPAC inhibitor (filled triangles)-, and PI3K/Akt inhibitor (filled circles)-treated rats after AIH, and time control (without AIH, gray diamonds)-treated rats. pLTF is significant in vehicle-treated rats versus EPACi-treated rats at 30-, 60-, and 90-min posthypoxia ($), and at all time-points post-AIH versus time control-treated rats (*), baseline (+), PKAi (#), and PI3K/Akti (&) (all P < 0.05). PKAi-treated rats showed significant pLTF versus baseline at 30-, 60-, and 90-min posthypoxia, and time control-treated rats at 90-min posthypoxia (all P < 0.05). F: frequency (change from baseline; bursts/min) in vehicle-, PKA inhibitor-, EPAC inhibitor-, and PI3K/Akt inhibitor-treated rats after AIH, and time control-treated rats. Small frequency LTF in vehicle-treated rats is observed at 30- and 60-min post-AIH versus baseline (+) (P < 0.05). PI3K/Akti-treated rats had decreased frequency LTF compared with baseline (+) at 15-min post-AIH (P < 0.05). A two-way ANOVA with repeated measures design was utilized, followed by a <t>Tukey</t> <t>post</t> hoc test. Values are means ± SE. AIH, acute intermittent hypoxia; EPAC, exchange protein activated by cyclic AMP; LTF, long-term facilitation; PI3K/Akt, phosphatidylinositol 3-kinase/Akt; pLTF, phrenic long-term facilitation; sAIH, severe AIH. The n for each group is as follows: vehicle 1, n = 10; ESI-05, n = 5; PI828, n = 5; KT-5720, n = 8; time control, n = 10.
Z Test Sigmaplot V14, supplied by SYSTAT, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/z-test sigmaplot v14/product/SYSTAT
Average 90 stars, based on 1 article reviews
z-test sigmaplot v14 - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
sigmaplot v.12 v.14  (SYSTAT)
90
SYSTAT sigmaplot v.12 v.14
pLTF is abolished following ESI-05 and PI828 treatment. A–D: representative traces of compressed, integrated phrenic nerve activity before and after sAIH following pretreatment with vehicle (A), ESI-05 (EPAC inhibitor, B), PI828 (PI3K/Akt inhibitor, C), and KT-5720 (PKA inhibitor, D). The dashed line in each trace represents baseline. E: phrenic burst amplitude (percent change from baseline) in vehicle (open diamonds)-, PKA inhibitor (filled squares)-, EPAC inhibitor (filled triangles)-, and PI3K/Akt inhibitor (filled circles)-treated rats after AIH, and time control (without AIH, gray diamonds)-treated rats. pLTF is significant in vehicle-treated rats versus EPACi-treated rats at 30-, 60-, and 90-min posthypoxia ($), and at all time-points post-AIH versus time control-treated rats (*), baseline (+), PKAi (#), and PI3K/Akti (&) (all P < 0.05). PKAi-treated rats showed significant pLTF versus baseline at 30-, 60-, and 90-min posthypoxia, and time control-treated rats at 90-min posthypoxia (all P < 0.05). F: frequency (change from baseline; bursts/min) in vehicle-, PKA inhibitor-, EPAC inhibitor-, and PI3K/Akt inhibitor-treated rats after AIH, and time control-treated rats. Small frequency LTF in vehicle-treated rats is observed at 30- and 60-min post-AIH versus baseline (+) (P < 0.05). PI3K/Akti-treated rats had decreased frequency LTF compared with baseline (+) at 15-min post-AIH (P < 0.05). A two-way ANOVA with repeated measures design was utilized, followed by a <t>Tukey</t> <t>post</t> hoc test. Values are means ± SE. AIH, acute intermittent hypoxia; EPAC, exchange protein activated by cyclic AMP; LTF, long-term facilitation; PI3K/Akt, phosphatidylinositol 3-kinase/Akt; pLTF, phrenic long-term facilitation; sAIH, severe AIH. The n for each group is as follows: vehicle 1, n = 10; ESI-05, n = 5; PI828, n = 5; KT-5720, n = 8; time control, n = 10.
Sigmaplot V.12 V.14, supplied by SYSTAT, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/sigmaplot v.12 v.14/product/SYSTAT
Average 90 stars, based on 1 article reviews
sigmaplot v.12 v.14 - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
computer spreadsheet statistical analysis package sigmaplot v.14  (SYSTAT)
90
SYSTAT computer spreadsheet statistical analysis package sigmaplot v.14
pLTF is abolished following ESI-05 and PI828 treatment. A–D: representative traces of compressed, integrated phrenic nerve activity before and after sAIH following pretreatment with vehicle (A), ESI-05 (EPAC inhibitor, B), PI828 (PI3K/Akt inhibitor, C), and KT-5720 (PKA inhibitor, D). The dashed line in each trace represents baseline. E: phrenic burst amplitude (percent change from baseline) in vehicle (open diamonds)-, PKA inhibitor (filled squares)-, EPAC inhibitor (filled triangles)-, and PI3K/Akt inhibitor (filled circles)-treated rats after AIH, and time control (without AIH, gray diamonds)-treated rats. pLTF is significant in vehicle-treated rats versus EPACi-treated rats at 30-, 60-, and 90-min posthypoxia ($), and at all time-points post-AIH versus time control-treated rats (*), baseline (+), PKAi (#), and PI3K/Akti (&) (all P < 0.05). PKAi-treated rats showed significant pLTF versus baseline at 30-, 60-, and 90-min posthypoxia, and time control-treated rats at 90-min posthypoxia (all P < 0.05). F: frequency (change from baseline; bursts/min) in vehicle-, PKA inhibitor-, EPAC inhibitor-, and PI3K/Akt inhibitor-treated rats after AIH, and time control-treated rats. Small frequency LTF in vehicle-treated rats is observed at 30- and 60-min post-AIH versus baseline (+) (P < 0.05). PI3K/Akti-treated rats had decreased frequency LTF compared with baseline (+) at 15-min post-AIH (P < 0.05). A two-way ANOVA with repeated measures design was utilized, followed by a <t>Tukey</t> <t>post</t> hoc test. Values are means ± SE. AIH, acute intermittent hypoxia; EPAC, exchange protein activated by cyclic AMP; LTF, long-term facilitation; PI3K/Akt, phosphatidylinositol 3-kinase/Akt; pLTF, phrenic long-term facilitation; sAIH, severe AIH. The n for each group is as follows: vehicle 1, n = 10; ESI-05, n = 5; PI828, n = 5; KT-5720, n = 8; time control, n = 10.
Computer Spreadsheet Statistical Analysis Package Sigmaplot V.14, supplied by SYSTAT, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/computer spreadsheet statistical analysis package sigmaplot v.14/product/SYSTAT
Average 90 stars, based on 1 article reviews
computer spreadsheet statistical analysis package sigmaplot v.14 - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
sigmaplot v14.00  (SYSTAT)
90
SYSTAT sigmaplot v14.00
pLTF is abolished following ESI-05 and PI828 treatment. A–D: representative traces of compressed, integrated phrenic nerve activity before and after sAIH following pretreatment with vehicle (A), ESI-05 (EPAC inhibitor, B), PI828 (PI3K/Akt inhibitor, C), and KT-5720 (PKA inhibitor, D). The dashed line in each trace represents baseline. E: phrenic burst amplitude (percent change from baseline) in vehicle (open diamonds)-, PKA inhibitor (filled squares)-, EPAC inhibitor (filled triangles)-, and PI3K/Akt inhibitor (filled circles)-treated rats after AIH, and time control (without AIH, gray diamonds)-treated rats. pLTF is significant in vehicle-treated rats versus EPACi-treated rats at 30-, 60-, and 90-min posthypoxia ($), and at all time-points post-AIH versus time control-treated rats (*), baseline (+), PKAi (#), and PI3K/Akti (&) (all P < 0.05). PKAi-treated rats showed significant pLTF versus baseline at 30-, 60-, and 90-min posthypoxia, and time control-treated rats at 90-min posthypoxia (all P < 0.05). F: frequency (change from baseline; bursts/min) in vehicle-, PKA inhibitor-, EPAC inhibitor-, and PI3K/Akt inhibitor-treated rats after AIH, and time control-treated rats. Small frequency LTF in vehicle-treated rats is observed at 30- and 60-min post-AIH versus baseline (+) (P < 0.05). PI3K/Akti-treated rats had decreased frequency LTF compared with baseline (+) at 15-min post-AIH (P < 0.05). A two-way ANOVA with repeated measures design was utilized, followed by a <t>Tukey</t> <t>post</t> hoc test. Values are means ± SE. AIH, acute intermittent hypoxia; EPAC, exchange protein activated by cyclic AMP; LTF, long-term facilitation; PI3K/Akt, phosphatidylinositol 3-kinase/Akt; pLTF, phrenic long-term facilitation; sAIH, severe AIH. The n for each group is as follows: vehicle 1, n = 10; ESI-05, n = 5; PI828, n = 5; KT-5720, n = 8; time control, n = 10.
Sigmaplot V14.00, supplied by SYSTAT, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/sigmaplot v14.00/product/SYSTAT
Average 90 stars, based on 1 article reviews
sigmaplot v14.00 - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
graphics software sigmaplot v. 14  (SYSTAT)
90
SYSTAT graphics software sigmaplot v. 14
pLTF is abolished following ESI-05 and PI828 treatment. A–D: representative traces of compressed, integrated phrenic nerve activity before and after sAIH following pretreatment with vehicle (A), ESI-05 (EPAC inhibitor, B), PI828 (PI3K/Akt inhibitor, C), and KT-5720 (PKA inhibitor, D). The dashed line in each trace represents baseline. E: phrenic burst amplitude (percent change from baseline) in vehicle (open diamonds)-, PKA inhibitor (filled squares)-, EPAC inhibitor (filled triangles)-, and PI3K/Akt inhibitor (filled circles)-treated rats after AIH, and time control (without AIH, gray diamonds)-treated rats. pLTF is significant in vehicle-treated rats versus EPACi-treated rats at 30-, 60-, and 90-min posthypoxia ($), and at all time-points post-AIH versus time control-treated rats (*), baseline (+), PKAi (#), and PI3K/Akti (&) (all P < 0.05). PKAi-treated rats showed significant pLTF versus baseline at 30-, 60-, and 90-min posthypoxia, and time control-treated rats at 90-min posthypoxia (all P < 0.05). F: frequency (change from baseline; bursts/min) in vehicle-, PKA inhibitor-, EPAC inhibitor-, and PI3K/Akt inhibitor-treated rats after AIH, and time control-treated rats. Small frequency LTF in vehicle-treated rats is observed at 30- and 60-min post-AIH versus baseline (+) (P < 0.05). PI3K/Akti-treated rats had decreased frequency LTF compared with baseline (+) at 15-min post-AIH (P < 0.05). A two-way ANOVA with repeated measures design was utilized, followed by a <t>Tukey</t> <t>post</t> hoc test. Values are means ± SE. AIH, acute intermittent hypoxia; EPAC, exchange protein activated by cyclic AMP; LTF, long-term facilitation; PI3K/Akt, phosphatidylinositol 3-kinase/Akt; pLTF, phrenic long-term facilitation; sAIH, severe AIH. The n for each group is as follows: vehicle 1, n = 10; ESI-05, n = 5; PI828, n = 5; KT-5720, n = 8; time control, n = 10.
Graphics Software Sigmaplot V. 14, supplied by SYSTAT, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/graphics software sigmaplot v. 14/product/SYSTAT
Average 90 stars, based on 1 article reviews
graphics software sigmaplot v. 14 - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
tukey’s hsd multicomparison test sigmaplot v.14  (SYSTAT)
90
SYSTAT tukey’s hsd multicomparison test sigmaplot v.14
pLTF is abolished following ESI-05 and PI828 treatment. A–D: representative traces of compressed, integrated phrenic nerve activity before and after sAIH following pretreatment with vehicle (A), ESI-05 (EPAC inhibitor, B), PI828 (PI3K/Akt inhibitor, C), and KT-5720 (PKA inhibitor, D). The dashed line in each trace represents baseline. E: phrenic burst amplitude (percent change from baseline) in vehicle (open diamonds)-, PKA inhibitor (filled squares)-, EPAC inhibitor (filled triangles)-, and PI3K/Akt inhibitor (filled circles)-treated rats after AIH, and time control (without AIH, gray diamonds)-treated rats. pLTF is significant in vehicle-treated rats versus EPACi-treated rats at 30-, 60-, and 90-min posthypoxia ($), and at all time-points post-AIH versus time control-treated rats (*), baseline (+), PKAi (#), and PI3K/Akti (&) (all P < 0.05). PKAi-treated rats showed significant pLTF versus baseline at 30-, 60-, and 90-min posthypoxia, and time control-treated rats at 90-min posthypoxia (all P < 0.05). F: frequency (change from baseline; bursts/min) in vehicle-, PKA inhibitor-, EPAC inhibitor-, and PI3K/Akt inhibitor-treated rats after AIH, and time control-treated rats. Small frequency LTF in vehicle-treated rats is observed at 30- and 60-min post-AIH versus baseline (+) (P < 0.05). PI3K/Akti-treated rats had decreased frequency LTF compared with baseline (+) at 15-min post-AIH (P < 0.05). A two-way ANOVA with repeated measures design was utilized, followed by a <t>Tukey</t> <t>post</t> hoc test. Values are means ± SE. AIH, acute intermittent hypoxia; EPAC, exchange protein activated by cyclic AMP; LTF, long-term facilitation; PI3K/Akt, phosphatidylinositol 3-kinase/Akt; pLTF, phrenic long-term facilitation; sAIH, severe AIH. The n for each group is as follows: vehicle 1, n = 10; ESI-05, n = 5; PI828, n = 5; KT-5720, n = 8; time control, n = 10.
Tukey’s Hsd Multicomparison Test Sigmaplot V.14, supplied by SYSTAT, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/tukey’s hsd multicomparison test sigmaplot v.14/product/SYSTAT
Average 90 stars, based on 1 article reviews
tukey’s hsd multicomparison test sigmaplot v.14 - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
sigmaplot v. 14.5 software  (SPSS Inc)
90
SPSS Inc sigmaplot v. 14.5 software
pLTF is abolished following ESI-05 and PI828 treatment. A–D: representative traces of compressed, integrated phrenic nerve activity before and after sAIH following pretreatment with vehicle (A), ESI-05 (EPAC inhibitor, B), PI828 (PI3K/Akt inhibitor, C), and KT-5720 (PKA inhibitor, D). The dashed line in each trace represents baseline. E: phrenic burst amplitude (percent change from baseline) in vehicle (open diamonds)-, PKA inhibitor (filled squares)-, EPAC inhibitor (filled triangles)-, and PI3K/Akt inhibitor (filled circles)-treated rats after AIH, and time control (without AIH, gray diamonds)-treated rats. pLTF is significant in vehicle-treated rats versus EPACi-treated rats at 30-, 60-, and 90-min posthypoxia ($), and at all time-points post-AIH versus time control-treated rats (*), baseline (+), PKAi (#), and PI3K/Akti (&) (all P < 0.05). PKAi-treated rats showed significant pLTF versus baseline at 30-, 60-, and 90-min posthypoxia, and time control-treated rats at 90-min posthypoxia (all P < 0.05). F: frequency (change from baseline; bursts/min) in vehicle-, PKA inhibitor-, EPAC inhibitor-, and PI3K/Akt inhibitor-treated rats after AIH, and time control-treated rats. Small frequency LTF in vehicle-treated rats is observed at 30- and 60-min post-AIH versus baseline (+) (P < 0.05). PI3K/Akti-treated rats had decreased frequency LTF compared with baseline (+) at 15-min post-AIH (P < 0.05). A two-way ANOVA with repeated measures design was utilized, followed by a <t>Tukey</t> <t>post</t> hoc test. Values are means ± SE. AIH, acute intermittent hypoxia; EPAC, exchange protein activated by cyclic AMP; LTF, long-term facilitation; PI3K/Akt, phosphatidylinositol 3-kinase/Akt; pLTF, phrenic long-term facilitation; sAIH, severe AIH. The n for each group is as follows: vehicle 1, n = 10; ESI-05, n = 5; PI828, n = 5; KT-5720, n = 8; time control, n = 10.
Sigmaplot V. 14.5 Software, supplied by SPSS Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/sigmaplot v. 14.5 software/product/SPSS Inc
Average 90 stars, based on 1 article reviews
sigmaplot v. 14.5 software - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
sigmaplot v.14  (Rockware Incorporated)
90
Rockware Incorporated sigmaplot v.14
pLTF is abolished following ESI-05 and PI828 treatment. A–D: representative traces of compressed, integrated phrenic nerve activity before and after sAIH following pretreatment with vehicle (A), ESI-05 (EPAC inhibitor, B), PI828 (PI3K/Akt inhibitor, C), and KT-5720 (PKA inhibitor, D). The dashed line in each trace represents baseline. E: phrenic burst amplitude (percent change from baseline) in vehicle (open diamonds)-, PKA inhibitor (filled squares)-, EPAC inhibitor (filled triangles)-, and PI3K/Akt inhibitor (filled circles)-treated rats after AIH, and time control (without AIH, gray diamonds)-treated rats. pLTF is significant in vehicle-treated rats versus EPACi-treated rats at 30-, 60-, and 90-min posthypoxia ($), and at all time-points post-AIH versus time control-treated rats (*), baseline (+), PKAi (#), and PI3K/Akti (&) (all P < 0.05). PKAi-treated rats showed significant pLTF versus baseline at 30-, 60-, and 90-min posthypoxia, and time control-treated rats at 90-min posthypoxia (all P < 0.05). F: frequency (change from baseline; bursts/min) in vehicle-, PKA inhibitor-, EPAC inhibitor-, and PI3K/Akt inhibitor-treated rats after AIH, and time control-treated rats. Small frequency LTF in vehicle-treated rats is observed at 30- and 60-min post-AIH versus baseline (+) (P < 0.05). PI3K/Akti-treated rats had decreased frequency LTF compared with baseline (+) at 15-min post-AIH (P < 0.05). A two-way ANOVA with repeated measures design was utilized, followed by a <t>Tukey</t> <t>post</t> hoc test. Values are means ± SE. AIH, acute intermittent hypoxia; EPAC, exchange protein activated by cyclic AMP; LTF, long-term facilitation; PI3K/Akt, phosphatidylinositol 3-kinase/Akt; pLTF, phrenic long-term facilitation; sAIH, severe AIH. The n for each group is as follows: vehicle 1, n = 10; ESI-05, n = 5; PI828, n = 5; KT-5720, n = 8; time control, n = 10.
Sigmaplot V.14, supplied by Rockware Incorporated, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/sigmaplot v.14/product/Rockware Incorporated
Average 90 stars, based on 1 article reviews
sigmaplot v.14 - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

Image Search Results


pLTF is abolished following ESI-05 and PI828 treatment. A–D: representative traces of compressed, integrated phrenic nerve activity before and after sAIH following pretreatment with vehicle (A), ESI-05 (EPAC inhibitor, B), PI828 (PI3K/Akt inhibitor, C), and KT-5720 (PKA inhibitor, D). The dashed line in each trace represents baseline. E: phrenic burst amplitude (percent change from baseline) in vehicle (open diamonds)-, PKA inhibitor (filled squares)-, EPAC inhibitor (filled triangles)-, and PI3K/Akt inhibitor (filled circles)-treated rats after AIH, and time control (without AIH, gray diamonds)-treated rats. pLTF is significant in vehicle-treated rats versus EPACi-treated rats at 30-, 60-, and 90-min posthypoxia ($), and at all time-points post-AIH versus time control-treated rats (*), baseline (+), PKAi (#), and PI3K/Akti (&) (all P < 0.05). PKAi-treated rats showed significant pLTF versus baseline at 30-, 60-, and 90-min posthypoxia, and time control-treated rats at 90-min posthypoxia (all P < 0.05). F: frequency (change from baseline; bursts/min) in vehicle-, PKA inhibitor-, EPAC inhibitor-, and PI3K/Akt inhibitor-treated rats after AIH, and time control-treated rats. Small frequency LTF in vehicle-treated rats is observed at 30- and 60-min post-AIH versus baseline (+) (P < 0.05). PI3K/Akti-treated rats had decreased frequency LTF compared with baseline (+) at 15-min post-AIH (P < 0.05). A two-way ANOVA with repeated measures design was utilized, followed by a Tukey post hoc test. Values are means ± SE. AIH, acute intermittent hypoxia; EPAC, exchange protein activated by cyclic AMP; LTF, long-term facilitation; PI3K/Akt, phosphatidylinositol 3-kinase/Akt; pLTF, phrenic long-term facilitation; sAIH, severe AIH. The n for each group is as follows: vehicle 1, n = 10; ESI-05, n = 5; PI828, n = 5; KT-5720, n = 8; time control, n = 10.

Journal: Journal of Neurophysiology

Article Title: Mechanisms of severe acute intermittent hypoxia-induced phrenic long-term facilitation

doi: 10.1152/jn.00691.2020

Figure Lengend Snippet: pLTF is abolished following ESI-05 and PI828 treatment. A–D: representative traces of compressed, integrated phrenic nerve activity before and after sAIH following pretreatment with vehicle (A), ESI-05 (EPAC inhibitor, B), PI828 (PI3K/Akt inhibitor, C), and KT-5720 (PKA inhibitor, D). The dashed line in each trace represents baseline. E: phrenic burst amplitude (percent change from baseline) in vehicle (open diamonds)-, PKA inhibitor (filled squares)-, EPAC inhibitor (filled triangles)-, and PI3K/Akt inhibitor (filled circles)-treated rats after AIH, and time control (without AIH, gray diamonds)-treated rats. pLTF is significant in vehicle-treated rats versus EPACi-treated rats at 30-, 60-, and 90-min posthypoxia ($), and at all time-points post-AIH versus time control-treated rats (*), baseline (+), PKAi (#), and PI3K/Akti (&) (all P < 0.05). PKAi-treated rats showed significant pLTF versus baseline at 30-, 60-, and 90-min posthypoxia, and time control-treated rats at 90-min posthypoxia (all P < 0.05). F: frequency (change from baseline; bursts/min) in vehicle-, PKA inhibitor-, EPAC inhibitor-, and PI3K/Akt inhibitor-treated rats after AIH, and time control-treated rats. Small frequency LTF in vehicle-treated rats is observed at 30- and 60-min post-AIH versus baseline (+) (P < 0.05). PI3K/Akti-treated rats had decreased frequency LTF compared with baseline (+) at 15-min post-AIH (P < 0.05). A two-way ANOVA with repeated measures design was utilized, followed by a Tukey post hoc test. Values are means ± SE. AIH, acute intermittent hypoxia; EPAC, exchange protein activated by cyclic AMP; LTF, long-term facilitation; PI3K/Akt, phosphatidylinositol 3-kinase/Akt; pLTF, phrenic long-term facilitation; sAIH, severe AIH. The n for each group is as follows: vehicle 1, n = 10; ESI-05, n = 5; PI828, n = 5; KT-5720, n = 8; time control, n = 10.

Article Snippet: With statistically significant ANOVAs, individual comparisons were made using Tukey post hoc test (SigmaPlot v. 14.0; Systat Software Inc., San Jose, CA).

Techniques: Activity Assay, Control

pLTF is abolished following UO126, but marginally constrained by apocynin treatment. A–C: representative traces of compressed, integrated phrenic nerve activity before and after sAIH following pretreatment with vehicle (A), UO126 (MEK/ERK inhibitor, B), and apocynin (NADPH oxidase or NOX inhibitor, C). The dashed line in each trace represents baseline. D: phrenic burst amplitude (percent change from baseline) in vehicle (open diamonds)-, NOX inhibitor (filled squares)-, and MEK/ERK inhibitor (filled triangles)-treated rats after AIH, and time control (without AIH, gray diamonds)-treated rats. pLTF is significant in vehicle-treated rats at all time-points post-AIH versus time control-treated rats (*) and baseline (+), and versus MEK/ERKi-treated rats at 60- and 90-min posthypoxia ($) (all P < 0.05). NOXi-treated rats showed significant pLTF versus baseline, time control-treated rats, and MEK/ERKi-treated rats at all time-points post-AIH (all P < 0.05). E: Frequency (change from baseline; bursts/min) in vehicle-, NOX inhibitor-, and MEK/ERK inhibitor-treated rats after AIH, and time control-treated rats. Small frequency LTF in NOXi-treated rats is observed at all time points post-AIH versus MEK/ERKi-treated rats ($), but only at 30- and 90-min post-AIH versus baseline (+) and time control-treated rats (*) (P < 0.05). MEK/ERKi-treated rats had decreased frequency LTF compared with time control-treated rats (*) and baseline (+) at 15-min post-AIH and compared with vehicle-treated rats at 15- and 30-min post-AIH (#) (all P < 0.05). A two-way ANOVA with repeated measures design followed by a Tukey post hoc test was utilized. Values are means ± SE. AIH, acute intermittent hypoxia; LTF, long-term facilitation; PI3K/Akt, phosphatidylinositol 3-kinase/Akt; pLTF, phrenic long-term facilitation; sAIH, severe AIH. The n for each group is as follows: vehicle 2, n = 10; UO126, n = 5; apocynin, n = 5; time control, n = 7.

Journal: Journal of Neurophysiology

Article Title: Mechanisms of severe acute intermittent hypoxia-induced phrenic long-term facilitation

doi: 10.1152/jn.00691.2020

Figure Lengend Snippet: pLTF is abolished following UO126, but marginally constrained by apocynin treatment. A–C: representative traces of compressed, integrated phrenic nerve activity before and after sAIH following pretreatment with vehicle (A), UO126 (MEK/ERK inhibitor, B), and apocynin (NADPH oxidase or NOX inhibitor, C). The dashed line in each trace represents baseline. D: phrenic burst amplitude (percent change from baseline) in vehicle (open diamonds)-, NOX inhibitor (filled squares)-, and MEK/ERK inhibitor (filled triangles)-treated rats after AIH, and time control (without AIH, gray diamonds)-treated rats. pLTF is significant in vehicle-treated rats at all time-points post-AIH versus time control-treated rats (*) and baseline (+), and versus MEK/ERKi-treated rats at 60- and 90-min posthypoxia ($) (all P < 0.05). NOXi-treated rats showed significant pLTF versus baseline, time control-treated rats, and MEK/ERKi-treated rats at all time-points post-AIH (all P < 0.05). E: Frequency (change from baseline; bursts/min) in vehicle-, NOX inhibitor-, and MEK/ERK inhibitor-treated rats after AIH, and time control-treated rats. Small frequency LTF in NOXi-treated rats is observed at all time points post-AIH versus MEK/ERKi-treated rats ($), but only at 30- and 90-min post-AIH versus baseline (+) and time control-treated rats (*) (P < 0.05). MEK/ERKi-treated rats had decreased frequency LTF compared with time control-treated rats (*) and baseline (+) at 15-min post-AIH and compared with vehicle-treated rats at 15- and 30-min post-AIH (#) (all P < 0.05). A two-way ANOVA with repeated measures design followed by a Tukey post hoc test was utilized. Values are means ± SE. AIH, acute intermittent hypoxia; LTF, long-term facilitation; PI3K/Akt, phosphatidylinositol 3-kinase/Akt; pLTF, phrenic long-term facilitation; sAIH, severe AIH. The n for each group is as follows: vehicle 2, n = 10; UO126, n = 5; apocynin, n = 5; time control, n = 7.

Article Snippet: With statistically significant ANOVAs, individual comparisons were made using Tukey post hoc test (SigmaPlot v. 14.0; Systat Software Inc., San Jose, CA).

Techniques: Activity Assay, Control

Direct comparison of the change in burst amplitude (percent baseline) and burst frequency (bursts/min) of the phrenic nerve following sAIH at 90-min posthypoxia. A and B: change in phrenic burst amplitude (A) or burst frequency (B) following pretreatment with vehicle, EPAC inhibitor (EPACi), PI3K/Akt inhibitor (PI3K/Akti), PKA inhibitor (PKAi), MEK/ERK inhibitor (MEK/ERKi), NADPH oxidase inhibitor (NOXi), or rats treated as time controls. A: phrenic amplitude after AIH at 90-min posthypoxia is significantly higher in vehicle-treated rats and NOXi rats compared with all other groups B: phrenic burst frequency after AIH at 90-min posthypoxia is significantly higher in NOXi rats compared time control-treated rats, PKAi-treated rats, MEK/ERKi-treated rats, and PI3K/Akti-treated rats. * vs. time control-treated rats, < vs. PKAi-treated rats, # vs. vehicle-treated rats, @ vs. MEK/ERKi-treated rats, $ vs. EPACi-treated rats, and & vs. PI3K/Akti-treated rats; all P < 0.05. A one-way ANOVA followed by a Tukey post hoc test was utilized; values are means ± SE. AIH, acute intermittent hypoxia; EPAC, exchange protein activated by cyclic AMP; PI3K/Akt, phosphatidylinositol 3-kinase/Akt; sAIH, severe AIH; TC, time control.

Journal: Journal of Neurophysiology

Article Title: Mechanisms of severe acute intermittent hypoxia-induced phrenic long-term facilitation

doi: 10.1152/jn.00691.2020

Figure Lengend Snippet: Direct comparison of the change in burst amplitude (percent baseline) and burst frequency (bursts/min) of the phrenic nerve following sAIH at 90-min posthypoxia. A and B: change in phrenic burst amplitude (A) or burst frequency (B) following pretreatment with vehicle, EPAC inhibitor (EPACi), PI3K/Akt inhibitor (PI3K/Akti), PKA inhibitor (PKAi), MEK/ERK inhibitor (MEK/ERKi), NADPH oxidase inhibitor (NOXi), or rats treated as time controls. A: phrenic amplitude after AIH at 90-min posthypoxia is significantly higher in vehicle-treated rats and NOXi rats compared with all other groups B: phrenic burst frequency after AIH at 90-min posthypoxia is significantly higher in NOXi rats compared time control-treated rats, PKAi-treated rats, MEK/ERKi-treated rats, and PI3K/Akti-treated rats. * vs. time control-treated rats, < vs. PKAi-treated rats, # vs. vehicle-treated rats, @ vs. MEK/ERKi-treated rats, $ vs. EPACi-treated rats, and & vs. PI3K/Akti-treated rats; all P < 0.05. A one-way ANOVA followed by a Tukey post hoc test was utilized; values are means ± SE. AIH, acute intermittent hypoxia; EPAC, exchange protein activated by cyclic AMP; PI3K/Akt, phosphatidylinositol 3-kinase/Akt; sAIH, severe AIH; TC, time control.

Article Snippet: With statistically significant ANOVAs, individual comparisons were made using Tukey post hoc test (SigmaPlot v. 14.0; Systat Software Inc., San Jose, CA).

Techniques: Comparison, Control

Short-term hypoxic phrenic response. A and B: progressive augmentation of the short-term hypoxic phrenic response was observed in all sAIH-treated rats including vehicle-, EPAC inhibitor (EPACi)-, PI3K/Akt inhibitor (PI3K/Akti)-, PKA inhibitor-, MEK/ERK inhibitor (MEK/ERKi)-, and NADPH oxidase inhibitor (NOXi)-treated rats. 1, 2, and 3 represent hypoxic episodes for sAIH-treated rats or normoxic episodes for time control-treated rats. In A and B, the hypoxic response progressively increases with each episode (* indicates significantly different than 1; and + indicated significantly different from 3; both P < 0.05). There were no changes in time control-treated rats, and all treatment groups were significantly different from time control-treated rats (P < 0.05). A two-way ANOVA with repeated measures design followed by a Tukey post hoc test was utilized; values are means ± SE. AIH, acute intermittent hypoxia; EPAC, exchange protein activated by cyclic AMP; PI3K/Akt, phosphatidylinositol 3-kinase/Akt; sAIH, severe AIH; TC, time control.

Journal: Journal of Neurophysiology

Article Title: Mechanisms of severe acute intermittent hypoxia-induced phrenic long-term facilitation

doi: 10.1152/jn.00691.2020

Figure Lengend Snippet: Short-term hypoxic phrenic response. A and B: progressive augmentation of the short-term hypoxic phrenic response was observed in all sAIH-treated rats including vehicle-, EPAC inhibitor (EPACi)-, PI3K/Akt inhibitor (PI3K/Akti)-, PKA inhibitor-, MEK/ERK inhibitor (MEK/ERKi)-, and NADPH oxidase inhibitor (NOXi)-treated rats. 1, 2, and 3 represent hypoxic episodes for sAIH-treated rats or normoxic episodes for time control-treated rats. In A and B, the hypoxic response progressively increases with each episode (* indicates significantly different than 1; and + indicated significantly different from 3; both P < 0.05). There were no changes in time control-treated rats, and all treatment groups were significantly different from time control-treated rats (P < 0.05). A two-way ANOVA with repeated measures design followed by a Tukey post hoc test was utilized; values are means ± SE. AIH, acute intermittent hypoxia; EPAC, exchange protein activated by cyclic AMP; PI3K/Akt, phosphatidylinositol 3-kinase/Akt; sAIH, severe AIH; TC, time control.

Article Snippet: With statistically significant ANOVAs, individual comparisons were made using Tukey post hoc test (SigmaPlot v. 14.0; Systat Software Inc., San Jose, CA).

Techniques: Control